Latest news with #IRBM
Borneo Post
6 days ago
- Business
- Borneo Post
Sarawak targets seamless 13MP execution with IRBM, value management, says Premier
Abang Johari explains that IRBM would serve as the foundation of the framework by ensuring that all projects align with Sarawak's 2030 development goals through strategic planning, budgeting, monitoring and evaluation. – Photo by Roystein Emmor KUCHING (May 28): The Sarawak government will implement a comprehensive delivery framework to ensure the successful execution of the 13th Malaysia Plan (13MP) for the state's development from 2026 to 2030, said Premier Datuk Patinggi Tan Sri Abang Johari Tun Openg. He said the framework would incorporate Integrated Results-Based Management (IRBM), Results-Based Budgeting, and Value Management to enable seamless coordination and performance monitoring of all initiatives under the plan. 'A strong plan alone is not enough. Sarawak's future depends on how well we execute it and how accountable we are in delivering results. 'To ensure the success of the 13MP, we will implement a comprehensive delivery framework, incorporating Integrated Results-Based Management (IRBM), Results-Based Budgeting and Value Management for seamless coordination and performance monitoring,' he said in his winding-up speech at the State Legislative Assembly sitting here today. He explained that IRBM would serve as the foundation of the framework by ensuring that all projects align with Sarawak's 2030 development goals through strategic planning, budgeting, monitoring and evaluation. 'Results-Based Budgeting will enhance resource efficiency, linking funding to measurable outcomes,' he added. Abang Johari also stressed that every proposed project under the 13MP would undergo rigorous evaluation at the entry point to ensure its viability, readiness, and accurate cost estimation. 'Additionally, through Value at Entry, every proposed project will undergo a thorough assessment to ensure viability, readiness, and accurate cost estimation, reducing delays and improving execution,' he said. According to the Premier, Sarawak's 13MP will be driven by 10 high-level strategies and a reinforced focus on 15 socio-economic sectors and enablers in line with the Post-Covid-19 Development Strategy (PCDS) 2030. 'The 13th Malaysia Plan (2026-2030) serves as a crucial planning framework that reinforces our long-term vision,' he said. 'As we stand at the midpoint of PCDS 2030 and the final year of the 12th Malaysia Plan, we must now advance with speed, clarity and purpose.' He noted that the 13MP is designed to ensure Sarawak's development strategies and actions remain consistent with its aspirations, and are responsive to evolving economic, social, and governance dynamics. Among the 10 high-level strategies outlined are accelerating the clean energy transition, building a high-quality and inclusive society, optimising land use, attracting strategic industries, enhancing public safety and disaster preparedness, and fostering a strong and resilient Bumiputera business community. 13MP abang johari DUN IRBM
Malaysiakini
06-05-2025
- Business
- Malaysiakini
Understanding Malaysia's e-Invoice Timeline: Is Your Business Ready for the 2025 Mandate?
Malaysia's e-Invoicing system represents one of the most significant tax administration transformations in recent years. As implementation deadlines approach in 2025 and 2026, businesses across all sectors must prepare for this digital shift or risk falling behind in compliance. Malaysia's Phased e-Invoice Implementation Timeline The Inland Revenue Board of Malaysia (IRBM) has adopted a phased approach to e-Invoice implementation, giving businesses of different sizes varying timelines to prepare: Phase 1 (October 1, 2024) : Businesses with annual turnover exceeding RM100 million Phase 2 (January 1, 2025) : Businesses with annual turnover between RM25 million and RM100 million Phase 3 (July 1, 2025): Businesses with annual turnover between RM500,000 and RM25 million Phase 4 (January 1, 2026): Businesses with annual turnover between RM150,000 and RM500,000 This staggered implementation allows larger enterprises to lead the way while giving smaller businesses additional time to adapt their systems and processes. How Is Your Timeline Determined? Your business's implementation date is determined based on annual turnover or revenue, using either: The statement of comprehensive income in your 2022 audited financial statements, or Your annual revenue reported in the tax return for the year of assessment 2022 The implementation date is July 1, 2025, for new businesses established from 2023 onwards with revenue exceeding RM500,000. Those with revenue up to RM500,000 must comply by January 1, 2026. Businesses starting operations from 2025 onwards must implement e-Invoice by January 1, 2026, or upon commencement of operations. The 6-Month "Interim Relaxation Period" Recognising the challenges of transitioning to a new system, the Malaysian government has provided a six-month grace period following each implementation phase. During this interim relaxation period, businesses can: Issue consolidated e-Invoices for all activities and transactions, even for industries that would normally require individual e-Invoices Issue consolidated self-billed e-Invoices for all applicable circumstances Use simpler formats for transaction descriptions in consolidated e-Invoices Continue normal operations without prosecution action for non-compliance, provided they meet minimum requirements These concessions are designed to ease the transition, but businesses should still use this period to work toward full compliance before the relaxation period ends. Key Exemptions to Be Aware Of Wait, not all businesses and transactions fall under the e-Invoice mandate. Current exemptions include: Individuals not conducting business Businesses with an annual turnover below RM150,000 Foreign diplomatic offices Statutory bodies for certain functions (until July 1, 2025) International organisations (until July 1, 2025) Additionally, specific income and expenses are exempt, including employment income, pension, alimony, zakat, and certain types of dividend distributions. Assessing Your Business Readiness With less than a year remaining for many businesses, here's how to evaluate your preparedness: 1. Technical Infrastructure Assessment Do you have systems capable of generating e-Invoices in the required XML or JSON formats? Have you determined whether you'll use the MyInvois Portal or API integration? Is your accounting software compatible with e-invoice requirements, or will you need updates? 2. Process Readiness Have you mapped your current invoicing processes against e-Invoice requirements? Have you identified which classification codes apply to your common transactions? Are your staff trained on the new requirements and workflows? 3. Data Management Can you accurately capture all required fields for e-Invoices? Do you have systems to store your customers' Tax Identification Numbers (TINs)? How will you manage the transition period when some suppliers and customers are not yet e-Invoice compliant? Next Steps: Creating Your Implementation Roadmap If your business falls under Phase 3 or 4 (implementation in 2025-2026), now is the critical time to begin preparations: Form an implementation team that includes accounting, IT, and operations representatives Evaluate software options, including whether to use the free MyInvois Portal or invest in API integration Develop a data strategy for capturing required customer information Create training plans for staff who will handle invoicing processes Establish new SOPs that incorporate e-Invoice requirements Begin communicating with business partners about the upcoming changes The Benefits Beyond Compliance While e-Invoice implementation may seem like a compliance burden, forward-thinking businesses are recognising significant advantages: Reduced manual processing and paperwork Decreased errors in invoice processing Faster payment reconciliation Improved cash flow management Enhanced data analytics capabilities Reduced environmental impact through paperless operations These benefits often outweigh the initial implementation costs, especially for businesses that embrace the change as an opportunity to digitise and streamline financial workflows. Conclusion The 2025 e-Invoice mandate is approaching rapidly, and businesses in Malaysia must assess their readiness and begin preparations immediately. By understanding their implementation timeline, effectively leveraging the interim relaxation period, and creating a comprehensive implementation plan, they can navigate this transition smoothly while potentially unlocking new efficiencies in their financial operations. For those who have yet to start their e-Invoice journey, the time to act is now—before compliance becomes mandatory and your business faces potential penalties for non-compliance. About the Author Mr. Chin Chee Seng is the Independent Non-Executive Director of AutoCount and the Founder of CCS Group. This e-Invoice News series is a collaboration with AutoCount. The views expressed here are those of the author/contributor and do not necessarily represent the views of Malaysiakini.
Korea Herald
03-04-2025
- Health
- Korea Herald
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of disease-relevant cellular models. The platform integrates CRISPR-based methodologies, screening capabilities, cell engineering, and advanced molecular and cellular analysis to drive both target discovery and validation. To further enhance target validation, IRBM is expanding its genome editing toolkit with CRISPR tiling to systematically map functional domains within coding and regulatory regions, along with base and prime editing to introduce precise nucleotide modifications. These next-generation approaches—combined with the platform's high-throughput CRISPR screening, including stem cell engineering—are instrumental in building robust disease models and improving the reliability of target validation. "Understanding which targets are truly viable for drug development is a complex challenge," said Sara Tomaselli, PhD, Head of Functional Genomics at IRBM. "With this in-house platform, we're strengthening our ability to systematically evaluate gene function, de-risk early discovery, and support our partners in making well-informed decisions." The platform's screening capabilities include genome-wide and targeted CRISPR libraries for knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa), enabling in-depth exploration of gene function and associated pathways. In parallel, IRBM's cell engineering expertise—spanning patient-relevant models and iPSC-derived systems—supports disease modeling across oncology, neurodegeneration, and rare disorders. Multi-omics integration, including high-content imaging, single-cell transcriptomics, and proteomics, provides deeper functional characterization of drug targets. IRBM's Functional Genomics Platform is part of a broader, fully integrated drug discovery ecosystem, ensuring that genetic insights translate into meaningful preclinical models and drug development strategies. By combining functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM enables biopharma innovators to approach target validation with greater confidence. "We take a careful, methodical approach to functional genomics—one that integrates well with the complexities of drug discovery," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "Our goal is to help our partners uncover high-quality targets and generate data that can guide and inform decision making throughout the entire drug discovery process." IRBM's collaborative approach allows biotech startups, pharmaceutical companies, and venture-backed teams to access functional genomics expertise without the need for in-house infrastructure. With customized solutions spanning genetic screening, engineered cell models, and mechanistic studies, IRBM provides practical, scientifically rigorous support at key points in drug discovery. To learn more about IRBM's Functional Genomics Platform and collaboration opportunities, visit
Yahoo
03-04-2025
- Health
- Yahoo
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of disease-relevant cellular models. The platform integrates CRISPR-based methodologies, screening capabilities, cell engineering, and advanced molecular and cellular analysis to drive both target discovery and validation. To further enhance target validation, IRBM is expanding its genome editing toolkit with CRISPR tiling to systematically map functional domains within coding and regulatory regions, along with base and prime editing to introduce precise nucleotide modifications. These next-generation approaches—combined with the platform's high-throughput CRISPR screening, including stem cell engineering—are instrumental in building robust disease models and improving the reliability of target validation. "Understanding which targets are truly viable for drug development is a complex challenge," said Sara Tomaselli, PhD, Head of Functional Genomics at IRBM. "With this in-house platform, we're strengthening our ability to systematically evaluate gene function, de-risk early discovery, and support our partners in making well-informed decisions." The platform's screening capabilities include genome-wide and targeted CRISPR libraries for knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa), enabling in-depth exploration of gene function and associated pathways. In parallel, IRBM's cell engineering expertise—spanning patient-relevant models and iPSC-derived systems—supports disease modeling across oncology, neurodegeneration, and rare disorders. Multi-omics integration, including high-content imaging, single-cell transcriptomics, and proteomics, provides deeper functional characterization of drug targets. IRBM's Functional Genomics Platform is part of a broader, fully integrated drug discovery ecosystem, ensuring that genetic insights translate into meaningful preclinical models and drug development strategies. By combining functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM enables biopharma innovators to approach target validation with greater confidence. "We take a careful, methodical approach to functional genomics—one that integrates well with the complexities of drug discovery," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "Our goal is to help our partners uncover high-quality targets and generate data that can guide and inform decision making throughout the entire drug discovery process." IRBM's collaborative approach allows biotech startups, pharmaceutical companies, and venture-backed teams to access functional genomics expertise without the need for in-house infrastructure. With customized solutions spanning genetic screening, engineered cell models, and mechanistic studies, IRBM provides practical, scientifically rigorous support at key points in drug discovery. To learn more about IRBM's Functional Genomics Platform and collaboration opportunities, visit About IRBM IRBM is a contract research organization (CRO) focused on early-stage drug discovery. With a track record of delivering preclinical candidates across oncology, neurodegeneration, and infectious diseases, IRBM partners with biotech and pharmaceutical innovators to advance therapeutic development with scientific precision and transparency. SOURCE IRBM S.p.A. Sign in to access your portfolio
